Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05968690 | Naltrexone and Propranolol Combined With Immunotherapy | recruiting | Phase 1 | 12 | Sarah WeissOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05839912 |
| Excision of Lymph Node Trial (EXCILYNT) (Mel69)(EXCILYNT) |
| recruiting |
| N/A |
| 66 |
| Craig L Slingluff, JrOTHER |
| 1 |
| Sep 17, 2025 |
| clinicaltrials |
| NCT06880198 | Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma(MELA-IMPACT) | recruiting | N/A | 20 | Fondazione Melanoma OnlusOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07092670 | MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. | recruiting | — | 270 | Intergruppo Melanoma ItalianoOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04424719 | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)(SALOME) | recruiting | N/A | 700 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06942143 | An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05180942 | Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS(SOCRATES) | recruiting | — | 130 | Monash UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06204991 | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma(ADP-TILIL7) | recruiting | Phase 1 | 10 | Inge Marie SvaneOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06359860 | A Study of ST-1898 for Unresectable or Metastatic Melanoma | recruiting | Phase 1 / Phase 2 | 64 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07130032 | Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade(reICB) | recruiting | Phase 2 | 90 | EuroCityClinic LLCNETWORK | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06754904 | Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node(OMIT) | recruiting | N/A | 213 | D.J. (Dirk) GrünhagenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05868707 | OH2 Injection in Melanoma | recruiting | Phase 3 | 340 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | recruiting | Phase 1 / Phase 2 | 60 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT03315468 | French Clinical Datbase of Melanoma Patients (RIC-Mel)(RIC-Mel) | recruiting | — | 16,000 | Nantes University HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07050940 | Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study | recruiting | N/A | 35 | Azienda Ospedaliera di PerugiaOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04986748 | Using QPOP to Predict Treatment for Sarcomas and Melanomas | recruiting | — | 100 | National Cancer Centre, SingaporeOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06560905 | Preoperative Planning With PSMA-PET in Melanoma Surgery Trial(PPPIMS) | recruiting | Phase 2 | 16 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07031830 | APA (Adapted Physical Activity) for Patients With Advanced Melanoma(APA-M) | recruiting | — | 50 | University Hospital, RouenOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06643286 | Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma(Melanoma SCP) | recruiting | N/A | 180 | Erasmus Medical CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05867004 | Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma(ATPIC) | recruiting | — | 100 | Institut Claudius RegaudOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06970236 | Resistance Exercise in Patients With Ocular Melanoma(IHOPE) | recruiting | N/A | 40 | University of ValenciaOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06980740 | Video-Tumorboard PLUS(vTB+) | recruiting | — | 300 | University Hospital MuensterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | Krystal Biotech, Inc.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06965231 | Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial(FUMS-EDJS2024) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06952400 | The Registry Study of Genetic Alterations of Melanoma in Taiwan(Melanoma) | recruiting | — | 250 | National Health Research Institutes, TaiwanOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04576429 | Immune Profiles Evolution Under Immunotherapy for Melanoma(EPITHEM) | recruiting | N/A | 360 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06797297 | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy | recruiting | Phase 2 | 180 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05483400 | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors(TIRACAN) | recruiting | Phase 2 | 97 | University Medical Center GroningenOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03888950 | Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy(TEP-ANTI-PD1) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05899465 | Perioperative Treatment With Tranexamic Acid in Melanoma(PRIME) | recruiting | Phase 3 | 1,204 | University of AarhusOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06774989 | Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma(SPEBINI) | recruiting | — | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06488365 | In Vivo Liquid Biopsy of Melanoma (Cytophone)(Cytophone) | recruiting | N/A | 180 | CytoastraINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05251389 | FMT to Convert Response to Immunotherapy | recruiting | Phase 1 / Phase 2 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06861023 | Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus for Melanoma | recruiting | — | 10 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04793737 | Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases(PROMMEL) | recruiting | N/A | 27 | Karolinska University HospitalOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05983237 | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 50 | Jun GuoOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06363591 | WoW - Single- vs Two-staged Excisions of Thin Melanoma(WoW) | recruiting | N/A | 2,486 | Vastra Gotaland RegionOTHER_GOV | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05652673 | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | recruiting | N/A | 80 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06608420 | Precision Medicine for L/GCMN and Melanoma 1(Precis-mel 1) | recruiting | — | 6,000 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06784778 | Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.(COMO) | recruiting | — | 196 | Pamgene International B.V.INDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2025source: clinicaltrials